Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab

Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab

Summary: The use of cetuximab anti-epidermal growth factor receptor (anti-EGFR) antibodies has opened the era of targeted and personalized therapy in colorectal cancer (CRC). Poor response rates have been unequivocally shown in mutant KRAS and are even observed in a majority of wild-type KRAS tumors...

Full description

Bibliographic Details
Main Authors: Justine Bellier, Marie-Julie Nokin, Maurine Caprasse, Assia Tiamiou, Arnaud Blomme, Jean L. Scheijen, Benjamin Koopmansch, Gillian M. MacKay, Barbara Chiavarina, Brunella Costanza, Gilles Rademaker, Florence Durieux, Ferman Agirman, Naïma Maloujahmoum, Pino G. Cusumano, Pierre Lovinfosse, Hing Y. Leung, Frédéric Lambert, Vincent Bours, Casper G. Schalkwijk, Roland Hustinx, Olivier Peulen, Vincent Castronovo, Akeila Bellahcène
Format: Article
Language:English
Published: Elsevier 2020-02-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124720300218

Internet

http://www.sciencedirect.com/science/article/pii/S2211124720300218

Similar Items